Only information I’ve heard this week that has some connection…
“Sanofi is set to acquire Vigil Neuroscience, which as the name implies is a biotech company focused on neurodegenerative diseases in a $470 million deal.Under the terms of the agreement, Sanofi will acquire all outstanding common shares of Vigil for $8 per share in cash. In addition, Vigil shareholders will receive a non-transferrable CVR for each Vigil share, which will entitle its holders to receive a deferred cash payment of $2 per share, conditioned upon the first commercial sale of its drug, VG3927.VG3927 is a phase 1 small molecule drug meant to treat Alzheimer's. Similar drugs have been developed and approved by the FDA and are made by Eli Lilly and Likwembe, which is a joint venture between Biogen and the Japanese pharmaceutical company, Isai” From The Special Situations Report: A Biotech Boom: Rumored Deals, Bidding Wars, CVRs, Insider Transactions, and More! – The Special Situations Report Episode #22, 9 Jun 2025https://podcasts.apple.com/ca/podcast/the-special-situations-report/id1790149530?i=1000712073290&r=659This material may be protected by copyright.
CGS Price at posting:
$1.42 Sentiment: Buy Disclosure: Held
A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.
(20min delay)